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Background: Genotype-Driven Recruitment (GDR) is a research design that recruits research participants based on
genotype rather than based on the presence or absence of a particular condition or clinical outcome. Analyses of
the ethical issues of GDR studies, and the recommendations derived from these analyses, are based on GDR
research designs that make use of genetic information already collected in previous studies. However, as
genotyping becomes more affordable, it is expected that genotypic information will become a common part of the
information stored in biobanks and held in health care records. Furthermore, individuals will increasingly gain
knowledge of their own genotypes through Direct-to-Consumer services. One can therefore foresee that individuals
will be invited to participate not only in follow-up GDR studies but also in original GDR studies because genetic
information about them is available. These individuals may or may have not participated in research before and
may or may not be aware that their genetic information is available for research.
Discussion: From a conceptual point of view, we investigate whether the current ethics-related recommendations
for the conduct of GDR suffice for a broader array of circumstances under which genetic information can be
available. Our analysis reveals that the existing recommendations do not suffice for a broader use of GDR.
Summary: Our findings refocus attention on ethical issues which are neither new nor specific to GDR but which
place greater demand on coordinated solutions. These challenges and approaches for addressing them are
discussed.
Keywords: Genotype-Driven Recruitment, Feedback of results, Genetic testing, BiobanksBackground
Biobanks and genomic studies are accumulating large
numbers of samples and generating databases that create
novel research opportunities within the biomedical and
behavioural sciences. An increasingly important design
used in genetic research is called Genotype-Driven Re-
cruitment (GDR) [1,2]. In GDR, research participants
are not recruited based on the presence or absence of a
particular condition (e.g. diabetes or high blood pres-
sure) but are rather recruited based on their genotype
characteristics such as the presence of a particular gene
variant (e.g. a specific polymorphism or a gene deletion)
[1,2]. GDR is a particularly useful design for studying the
role of specific genotypes on health-related outcomes* Correspondence: isabelle.budin.ljosne@fhi.no
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distribution, and reproduction in any mediumincluding differences in disease susceptibility, differential
responses to interventions and treatments or normal vari-
ation in developmental outcomes. GDR studies have great
potential to increase the utility of genomic data generated
in diverse settings and thereby can accelerate the transla-
tional process towards benefiting human health [1-3].
The ethical implications of GDR have been recently
discussed in the literature and recommendations have
been made to address these issues [1-18]. However, these
recommendations were derived from analyses of GDR
designs that recruit via re-contact of individuals for
whom genetic data already exists because they have par-
ticipated in a study that collected and analyzed DNA. In
this paper, we examine from a conceptual point of view,
whether the ethics-related recommendations which have
been proposed under circumstances of re-contact for
GDR research sufficiently cover the ethical concerns that
can arise as opportunities to use GDR increase with the
growing availability of genotypic data. In particular, weentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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individuals in original GDR studies because genetic infor-
mation about them is known or available through, for ex-
ample, health care medical records or health records from
Direct-to-Consumer (DTC) genetic testing services. These
individuals may or may have not participated in research
before and may or may not be aware that their genetic in-
formation is available for research.
Potential future uses of GDR
Current studies employing GDR are primarily follow-up
studies making secondary use of genetic information col-
lected in previous studies [1-3,7,9,14,17]. As genotyping
becomes more affordable, the use of GDR studies will
most likely expand for two main reasons. First, individ-
uals may be recruited into GDR studies because their
genetic information is made available through the health
care system. Several projects are currently planning to
sequence entire populations or large groups of individ-
uals and store their genetic information in healthcare da-
tabases. These projects are designed with the objective
to 1) offer better disease diagnosis, therapy and clinical
outcome for patients through integrated analysis of clin-
ical, biological, environmental and genetic data [19] and
2) produce datasets that may be made available to na-
tional and international researchers through the ap-
proval of data access applications. For example, the
FarGen project [20] plans to sequence the whole popula-
tion of the Faroe Islands (approximately 50,000 individ-
uals) within the coming years. The population of the
Faroe Islands is particularly interesting for researchers
because it is a small homogenous population with a high
incidence of rare hereditary diseases [21]. It is therefore
expected that the genetic information produced through
the FarGen project will be an attractive resource to con-
duct GDR studies. Another example is the British Na-
tional Health Service’s (NHS) plan to build a massive
database in which every British citizen’s DNA records
will be stored and made accessible to researchers from
public and private institutions [22,23]. Both the Faroese
and the British project plan that the genetic data pro-
duced will be stored in patient records and linkable to
other health registries [20,23]. These types of collections
are invaluable for conducting GDR studies that will play
an important role in advancing the goals of precision
medicine [19]. Although it is still unclear which require-
ments and limitations will apply for access to the data
produced through these projects (e.g. access to coded or
encrypted datasets), one can foresee that GDR will be in
high demand and procedures to conduct GDR will need
to be established.
A second reason why the potential to recruit individuals
through GDR may increase is because an individual’s gen-
etic information may be made available through DTCgenetic testing companies. The last years have seen the
emergence of a myriad of private companies which offer
genetic screening services to consumers at an affordable
price [24]. The privacy policies of these companies often
do not guarantee that genetic data will not be shared with
third parties and sometimes even state that genetic data
may be shared for research purposes or sold in the event
of company dissolution, merger or acquisition [24,25]. For
instance, the DTC genetic testing company 23andMe is
now seeking collaborations with academic researchers to
maximise the scientific yield from their database [26]. The
company highlights that research on rare genotype-
phenotype combinations is one of the proposed areas of
collaboration [26]. It is also foreseen that future business
plans of DTC companies will give greater priority to sell-
ing DTC customer data to commercial entities to increase
their return on investment [27,28]. Under such conditions,
it is likely that the genetic data of the customers of DTC
companies could be made accessible to researchers who
want to conduct GDR studies.
If, as we believe, opportunities for GDR-based studies
expand with the growing generation of genotypic data it
is critical to investigate how this impacts the ethical
landscape of GDR.
Methods
A literature search was conducted using Pubmed and
Google Scholar to identify studies that describe a) ethical
issues in GDR-based research and, b) current recom-
mendations to address those issues. Only articles which
specifically discussed or mentioned the ethical aspects of
GDR were selected from the search results [1-18]. An
overview of the ethical issues identified and the recom-
mendations made to address each of these issues was
then compiled.
Next, a conceptual analysis was conducted that exam-
ined whether each of the ethical issues identified was
sufficiently handled under the current set of recommen-
dations for the cases where individuals were not re-
contacted for a follow-up GDR study but contacted to
participate in an original GDR study because their gen-
etic information is available in public or private health
care records. The information generated from this ana-
lysis is described herein and serves as the basis upon
which we conclude whether the current recommenda-
tions suffice under the broader utilization of GDR.
Results
Results of our literature review reveal that the main
ethical issues associated with GDR are related to the
re-contact of research participants and the disclosure to
them of their genetic information during the recruitment
phase [1-4,6,7,9,14,17]. Table 1 provides an overview of
our analysis results including the ethical concerns
Table 1 Overview of ethical concerns in GDR and assessment whether current recommendations suffice for a broader
use of GDR
Ethical concerns in GDR Published recommendations Do the recommendations suffice under a
broader use of GDR?
Risk of violating the individual’s privacy and
right not to know if genetic information is
implicitly unveiled during re-contact [1,3,4]
Inform about potential re-contact and future
disclosure in the informed consent of original
study [2,6,7,12]
No: informed consent process may not have
taken place before genotyping
Offer the individual the possibility to choose
whether she wants to be involved in future
GDR studies [2-4,6,7]
No: choice to participate in future GDR studies
may not have been given
Design re-contact process in consultation with
the Institutional Review Board (IRB) of the
original study [6,7]
No: contact with/identification of the IRB of the
original study may not be possible
Risk that the individual enrolled does not
understand why she is eligible for the GDR
study [9,14]
Take into consideration the context into which
the individual is invited to participate in GDR
(e.g. previous participation in research, previous
research focusing on similar condition) [6,7,14]
No: the research background of the individual
may be unknown to the researcher inviting to
join a GDR study
Risk of creating unnecessary anxiety and distress
for the individual re-contacted [1]
Contact by known and/or trusted health
professional [3,4,7]
No: the individual may receive an invitation to
participate in an original GDR study from
unknown researchers
Risk of deceiving the individual if he is not
informed about the reasons for enrolment [1]
Return genetic results to the individual more
systematically than in other research designs
[1,3,6,7,9,15,17]
No: the individual may not have been prepared
to receive genetic results
Risk of group/individual discrimination and/or
stigmatisation if re-identification is possible
through the analysis of the study’s pedigree
description [1]
Add randomly selected sub-groups in case-only
studies [1]
Yes: randomly selected sub-groups could also
be added in original GDR case-only studies
Risk of provoking emotional distress for the
individual if the results disclosed are uncertified,
have low clinical utility [1,3,5] or if they indicate
the presence of a rare variant of significance for
the health of the individual [1,4,9]
Return only results which are clear, concise, and
accurate and explain the meaning and utility of
the results [1,7,9,15,17,18]
No: individuals may not have been prepared to
receive genetic results
Use consistent disclosure criteria as agreed
beforehand with individuals [8,15]
No: process to reach agreement beforehand on
which results to return may not have taken place
Design the return of results process in
consultation with the IRB of the original study [7]
No: contact with the IRB of the original study
may not be possible
Take into consideration the context of the
research, the relationship between research and
research participant, and the degree of
vulnerability and dependence of the research
participant [5,7,9]
No: the personal/research background of the
individual may be unknown to the researcher
inviting to join a GDR study
Risk of making the individual re-contacted the
carrier of bad news for non-contacted family
members [1,4,9]
Include recruitment of family members as part
of the research protocol [4]
No: individuals may not have had the
opportunity to consent to the invitation of their
relatives into the GDR study
Risk of harassing the individual if multiple re-
contact for inclusion in GDR studies takes place
[1]
Make use of independent governance bodies
(e.g. centralised ethics committee or data access
committee) which can determine which
individuals to re-contact [2,10]
No: governance bodies may not be co-
ordinated across publicly funded and privately
funded projects
Inform the individual about the role of
governance bodies in the consent of the
original study [10]
No: informed consent process may not have
taken place before genotyping
Make use of flexible and less intrusive electronic
information exchange systems for
communication with research participants [2]
No: communication systems may not be
established between the researchers inviting to
participate in a GDR study and the individuals
receiving the invitation
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whether the current recommendations adequately address
the ethical concerns raised under a broader utilization of
GDR and the reasoning behind these determinations.Ethical concerns in GDR
GDR based on the secondary use of previously collected
genotype data requires that the research participants be
re-contacted for the purpose of recruitment into the
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recruitment, GDR may implicitly result in researchers
providing participants with some information about
their genotype as well as other information related to
their medical or health status [1]. However, providing
such information during recruitment might violate the
individual’s privacy and right not to know about their
own genetic information [1-4]. It may also create anxiety
and distress for the individual who might think that
something is wrong about her health since she has been
re-contacted [1,2]. By contrast, not providing such infor-
mation at recruitment may be perceived by the individ-
ual as a form of deception because she would not know
why she has been enrolled in the study [1].
Issues surrounding the divulgence of genetic results are at
the crux of the ethical considerations in GDR. Today, the re-
turn of research results from genetic studies to research par-
ticipants is a highly debated topic among scientists, ethicists
and policy makers [29-31]. Current guidelines typically sanc-
tion the return of genetic results if they are actionable or
clinically useful for the research participants [18,32-34].
However, to harness the full scientific potential of GDR de-
signs, it is quite likely that the genetic selection criteria for
recruiting participants will not meet the requirements of be-
ing actionable or clinically useful. Not providing genetic re-
sults may mask the reasons why participants have been
enrolled in the study [1,7], but disclosing genetic results re-
quires certain types of guidance for the participant. This
process is compounded when results are experimental,
partly unreliable or uncertified and may have serious conse-
quences for the research participants who may make further
health-related decisions based on shallow scientific ground
[1,3,5]. However, even when the results are verified in clin-
ical labs, the finding of a rare variant could also have dra-
matic consequences for the individuals concerned because
they may affect their health and make them the carriers of
bad news for their family members [1,4,9].
Re-contact for recruitment into a GDR study may also
put the individuals re-contacted and their relatives in a
difficult situation, especially if the study design (e.g. case
only study) allows outsiders to determine which genetic
variant is under study [1,2]. Finally, there is a risk that
individuals with rare genetic variants may begin to feel
overwhelmed if they receive numerous invitations to join
GDR studies [1,2]. This could, in the long term, discour-
age individuals from participating in research.
Published recommendations
A number of recommendations have been made to ad-
dress the issues surrounding the return of genetic results
described above and primarily focus on optimising the
informed consent process and developing mechanisms
for feedback of results to research participants. This is il-
lustrated by recommendations to 1) include informationabout potential re-contact and future disclosure in the
original consent [2,6,7,12]; 2) offer participants the op-
portunity to choose whether or not they want to be re-
contacted for future participation in GDR studies
[2-4,6,7]; and 3) ensure that re-contact occurs by a
known and trusted health professional [3,4,7].
In addition, it is recommended that independent govern-
ance bodies determine, in close co-operation with the In-
stitutional Review Boards (IRB) of the original studies,
which individuals to re-contact and how to re-contact
them [2,6,7,10]. Other recommendations include 1) choos-
ing a study design which prevents the involuntary disclos-
ure of information about the genetic profile of the research
participants to the outside world, e.g. by adding randomly
selected sub-groups in case-only studies [1]; 2) using less
stringent parameters for the return of results to research
participants than currently recommended in other genetic
research [1,3,6,7,9,15,17] and 3) return of results according
to specific criteria agreed upon in co-operation with the re-
search participants [8,15].
Finally, a general recommendation is that researchers
who plan to conduct GDR studies should take into con-
sideration the context of the research (e.g. was the original
study conducted by different researchers than the follow-
up GDR study?) and the relationship between the re-
searchers and the individuals they plan to invite [5,7,9].
Do the recommendations suffice under a broader use of
GDR?
Results from our conceptual analysis reveal that out of
15 recommendations proposed in the current literature
only one may suffice in the context of a broader use of
GDR. The recommendation to add randomly selected
sub-groups in case-only studies to avoid risks of stigma-
tisation when individuals are invited to GDR studies
may also be applicable when GDR studies are original
studies and not follow-up studies. For each of the
remaining fourteen recommendations, we found one or
several reasons why the current recommendations would
not suffice in a context of broader use of GDR designs.
These reasons are reported in Table 1 and can be
summarised as follows.
The individuals invited to enroll in an original GDR study
may not be prepared to receive such an invitation
Current recommendations presuppose that, at some point
in time, an informed consent process has taken place be-
tween researchers and participants; a process during
which information about potential future enrolment in
GDR studies has been provided and the opportunity for
participants to indicate whether they want to be involved
in future GDR has been given. Recommendations also
suggest that re-contact should be undertaken by a known
professional such as the principal investigator of the study
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this type of individual informed consent process may not
systematically take place in conjunction with the gener-
ation of genotypic information. An example would be
genotyping conducted through standard health care where
informed consent may not have been required. Individuals
who are not aware that genetic information exists about
them will probably be totally unprepared if contacted for
participation in a GDR study [14]. Even individuals who
have previous knowledge about their genotype from DTC
genetic testing services may not be aware that their gen-
etic information potentially could have been sold to or
shared with other private companies or researchers [25].
Thus, unexpected contact may come as a surprise and
provoke anger if the individuals contacted do not want to
know about own genetic information and do not want
their relatives to know [1,3,4,9].
The individuals invited to enroll in an original GDR study
may not be prepared to receive genetic research results
When individuals who have participated in previous re-
search are re-contacted for participation in a GDR study,
they already have some knowledge about what a re-
search study entails and what participating in research
means. They have taken the initiative to participate in
research and may have received some basic information
related to the genetic research aims by the investigators
of the original study. Things may be different for indi-
viduals who are not re-contacted but contacted for the
first time; individuals who have never participated in re-
search before and may not know anything about genetic
research. There is currently no empirical evidence on
the effects of receiving genetic results without having
been prepared to it. One could argue that the disclosure
of genetic research results to research participants nor-
mally does not trigger such distress as shown in recent
studies [35,36]. However, the recipients of genetic results
who participated in those studies already had a relation-
ship with the researchers or were aware of the presence
of a genetic variant in their family through a relative’s
participation in research or illness. If individuals are
recruited into original GDR studies through e.g. their
health care system or directly by a private company,
such a relationship and awareness may not exist.
Current recommendations also encourage applying a
lower threshold than usual for feedback of results from
GDR [1,3,6,7,9,15,17]. A sound feedback process that re-
spects the perspectives and wishes of participants typic-
ally requires taking into consideration the context of the
research and the relationship between the researcher
and the research participant [8,15]. However, if as we
postulate, GDR designs were used more broadly, it
would not always be possible for researchers to make
such an assessment because they may not knowanything about the individual’s previous involvement in
research.
The establishment of independent governance bodies to
coordinate all GDR research projects may be too
challenging
The current recommendations encourage the establish-
ment of independent governance bodies, e.g. centralised
ethics or data access committees, by the projects gener-
ating genetic information to manage all data access re-
quests, protect the privacy and confidentiality of datasets
and determine which individuals can be contacted and
by whom. The objective of establishing these committees
is to avoid harassing individuals by inviting them to mul-
tiple studies as could be the case, for example, for indi-
viduals carrying a rare genetic variant, and ensure that
ethical standards are respected [2,7,10]. Creation of such
committees raises several sets of questions. First, ques-
tions related to the legal authority of these committees
may emerge. For instance, under which legal framework,
national or international, would these committees be
established and operate? Could these committees have
authority both over publicly financed research projects
and private companies? As an example, DTC genetic
testing companies currently do not operate under the
same legal framework as publicly funded research pro-
jects [37] and, although attempts to regulate their activ-
ities have been made, they still benefit from a rather
loose legal framework [38]. Unless international regula-
tion requires that DTC genetic testing companies follow
the same rules (and report to the same centralised com-
mittees) as publicly funded research projects, it is quite
unlikely that they will do so.
Second, questions related to the scientific authority of
these committees may emerge. How could these com-
mittees for instance make decisions regarding data ac-
cess requests from numerous public and private
actors? To do so would probably require that the com-
mittees have extensive knowledge about all research
projects previously undergone, which individuals have
participated in which research projects and which have
not, which have consented to re-contact and which
have not, which have already been invited in previous
GDR studies, and which have not etc. Such a high level
of co-ordination could maybe be possible between
publicly-funded institutions within a specific research
collaboration or geographic area [10] but seem quite
unrealistic to expect when both publicly funded re-
search projects and a myriad of private companies are
involved.
Discussion
We investigated whether current recommendations to
address ethical issues in GDR suffice when GDR studies
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genetic information is available through, for example,
health care medical records or health records from DTC
genetic testing services. These individuals may or may
not have participated in a research study and may or
may not be aware that their genetic information is avail-
able for research. The current recommendations are use-
ful when planning studies that will produce genotypic
information of interest for future GDR. However, they
were not developed to address potential issues that may
arise if original GDR studies become more common due
to the availability of individual genotypic information
generated from a wider and more diverse array of
sources.
From a conceptual point of view, we foresee that a
broader use of GDR will call attention to a number of is-
sues that are neither new nor specific to GDR per se but
for which coordinated solutions will be strongly needed.
Examples include:
1) How to deal with the dissemination of genetic
information of uncertain value and utility towards
groups of individuals that are unaware that such
information exists about them and are insufficiently
educated to understand the meaning of it;
2) How to widely disseminate information about
genetic variants to individuals through the conduct
of GDR studies without provoking the unnecessary
medicalization of otherwise healthy individuals [39];
3) How to respectfully disseminate information about
genetic variation to individuals about their own
genotypes but which has implications at the familial
level [4,17];
4) How to avoid provoking more genetic determinism
and increasing potential risks of stigmatisation and
discrimination of individuals when genotypes
become a common selection criteria for invitation in
research studies [40]; and,
5) How to avoid invitation-fatigue of individuals whose
genotypes are highly sought after for biomedical
research.
Summary
There are growing opportunities for important research
using GDR designs and recent studies show that re-
search participants have a rather positive attitude to-
wards GDR designs and understand their scientific value
[3,9,15,17]. The recommendations that have been pub-
lished to address ethical concerns in GDR are useful but
should be complemented by other strategies to address
new challenges for GDR designs that originate outside of
a study-specific research setting. These strategies cannot
be addressed by the researchers conducting GDR studies
alone but need to be addressed at a broader level byhealth authorities, the scientific community from both
public and private sectors, and policy makers. Such
strategies may be bolstered by the development of tools
to promote education, dissemination and public engage-
ment. Examples include tools to: 1) widely inform the
public about genetic research activities and the produc-
tion of genetic information through health care systems
and private companies; 2) provide all groups in society
with basic education in genetics; 3) widely inform about
the right to opt-out from research and the right not to
know about one’s own genetic information; 4) protect
and secure these rights in a co-ordinated manner
across privately and publicly funded research projects,
and 5) facilitate an increased involvement of the public
in the design of research projects.
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